[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100571533":3},{"organization":4,"armGroups":7,"interventions":21,"overallOfficials":36,"centralContacts":40,"locations":49,"responsibleParty":69,"collaborators":71,"id":75,"slug":76,"hasResults":77,"nctId":78,"briefTitle":79,"officialTitle":80,"acronym":27,"eligibilityCriteria":81,"healthyVolunteers":77,"sex":82,"minAge":83,"maxAge":84,"enrollmentInfo":85,"targetDuration":27,"studyType":88,"phases":89,"briefSummary":91,"conditions":92,"keywords":27,"overallStatus":52,"whyStopped":27,"lastUpdateSubmitDate":96,"lastUpdatePostDateStruct":97,"startDateStruct":100,"completionDateStruct":102,"leadSponsor":104,"locationsCount":105},{"fullName":5,"class":6},"Clear Scientific, Inc.","INDUSTRY",[8,15],{"label":9,"type":10,"description":11,"interventionNames":12},"Placebo","PLACEBO_COMPARATOR","Participants receive methamphetamine HCl (30 mg) followed by placebo (saline).",[13,14],"Drug: Methamphetamine","Drug: Sterile Saline",{"label":16,"type":17,"description":18,"interventionNames":19},"Active","ACTIVE_COMPARATOR","Participants receive methamphetamine HCl (30 mg) followed by one of four doses of CS-1103",[13,20],"Drug: CS-1103",[22,28,32],{"type":23,"name":24,"description":25,"armGroupLabels":26,"otherNames":27},"DRUG","Methamphetamine","Methamphetamine HCl for intravenous administration",[16,9],null,{"type":23,"name":29,"description":30,"armGroupLabels":31,"otherNames":27},"Sterile Saline","Sterile Saline for intravenous administration",[9],{"type":23,"name":33,"description":34,"armGroupLabels":35,"otherNames":27},"CS-1103","CS-1103 for intravenous administration",[16],[37],{"name":38,"affiliation":5,"role":39},"Xinhua Li, Ph.D.","PRINCIPAL_INVESTIGATOR",[41,46],{"name":42,"role":43,"phone":44,"phoneExt":27,"email":45},"Anna Del Rosario, B.S.","CONTACT","617-621-8500","adelrosario@clearsci.com",{"name":47,"role":43,"phone":44,"phoneExt":27,"email":48},"Piercen Oliver, Ph.D.","poliver@clearsci.com",[50],{"facility":51,"status":52,"city":53,"state":54,"zip":55,"country":56,"countryCode":57,"cosmosGeoPoint":58,"geoPoint":63,"contacts":64},"California Clinical Trials Medical Group","RECRUITING","Glendale","California","91206","United States","US",{"type":59,"coordinates":60},"Point",[61,62],-118.25508,34.14251,{"lat":62,"lon":61},[65],{"name":66,"role":43,"phone":67,"phoneExt":27,"email":68},"Lev Gertsik, M.D.","888-228-7425","study.losangeles@parexel.com",{"type":70,"investigatorFullName":27,"investigatorTitle":27,"investigatorAffiliation":27,"oldNameTitle":27,"oldOrganization":27},"SPONSOR",[72],{"name":73,"class":74},"National Institute on Drug Abuse (NIDA)","NIH","100571533","phase-2-a-single-dose-study-to-evaluate-safety-and-efficacy-of-cs-1103-in-participants-receiving-a-single-dose-of-methamphetamine-100571533",false,"NCT06721494","A Single-Dose Study to Evaluate Safety and Efficacy of CS-1103 in Participants Receiving a Single Dose of Methamphetamine","A Phase 2 Single-Dose Study to Evaluate Safety and Efficacy of CS-1103 in Participants With Methamphetamine Use Disorder Not Seeking Treatment Receiving a Single Dose of Methamphetamine","Major Inclusion Criteria:\n\n1. Healthy participants aged 18 to 55 years, inclusive;\n2. Meets DSM-5 criteria for methamphetamine use disorder;\n3. Not seeking treatment for methamphetamine use disorder;\n4. Primary route of methamphetamine self-administration must be intravenous or smoking;\n5. Able to abstain from methamphetamine without experiencing severe withdrawal;\n6. A body mass index between 18 to 30 kg\u002Fm2, inclusive and a minimum body weight of 50 kg;\n7. Females must not be lactating and must have a negative pregnancy test during screening and admission.\n\nMajor Exclusion Criteria:\n\n1. Estimated glomerular filtration rate \\\u003C60 mL\u002Fmin\u002F1.73 m2;\n2. History of cardiovascular disease;\n3. Current moderate to severe use disorder for alcohol, cannabis, cocaine, opioids, or benzodiazepines;\n4. History of any clinically important disease or disorder which, in the opinion of the Investigator, may interfere with safe study participation.","ALL","18 Years","55 Years",{"count":86,"type":87},40,"ESTIMATED","INTERVENTIONAL",[90],"PHASE2","The purpose of the study is to evaluate the safety, efficacy, and pharmacokinetics of four single, increasing doses of CS-1103, given by intravenous (IV) infusion in otherwise healthy, non-treatment seeking participants with methamphetamine use disorder in the presence of a clinically relevant dose of methamphetamine HCl (30 mg IV).",[93,94,95],"Methamphetamine Intoxication","Methamphetamine Disorders","Methamphetamine Abuse","2026-01-09",{"date":98,"type":99},"2026-01-12","ACTUAL",{"date":101,"type":87},"2026-02-05",{"date":103,"type":87},"2026-09-11",{"name":5,"class":6},1]